← Back to Search

Other

Enzalutamide or Abiraterone or Apalutamid for Prostate Cancer

Phase 1
Waitlist Available
Research Sponsored by Kangpu Biopharmaceuticals, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to cycle-6 (28-day per cycle)
Awards & highlights

Study Summary

This trial is testing a new drug, KPG-121, to see if it is safe and effective in treating prostate cancer. The drug will be given orally once daily for 28 days, then the patient will have 7 days off. The study will enroll adult subjects who have either non-metastatic or metastatic castration-resistant prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to cycle-6 (28-day per cycle)
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to cycle-6 (28-day per cycle) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of KPG-121
Secondary outcome measures
Incidence of Adverse Events [Safety and Tolerability]
Pharmacokinetic (PK) profile of KPG-121

Trial Design

1Treatment groups
Experimental Treatment
Group I: KPG-121Experimental Treatment1 Intervention
Safety and Antitumor Activity of KPG-121 capsules at different dose level for 21 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enzalutamide or Abiraterone or Apalutamid
2019
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Kangpu Biopharmaceuticals, Ltd.Lead Sponsor
3 Previous Clinical Trials
134 Total Patients Enrolled
Yao Wang, MDStudy DirectorKangpu Biopharmacuticals
YONG GUO, MDStudy DirectorKangpu Biopharmacuticals

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
2019. "Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03569280.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top